Business Insights, June 2011, Pages: 187
and analyze the key technology platforms being used in the development of novel molecular diagnostics.
- Discover the forecast market size for key segments of the cancerdiagnostics market including: breast
Business Insights, Feb 2007, Pages: 105
based on the numbers of patients globally, 2002
Table 3.11: Cancer vaccine pipeline, 2006
Table 3.12: siRNA drug pipeline, 2006 Innovations in Cancer: NovelTherapeutics, New Diagnostics and Future R
Jain PharmaBiotech, Feb 2012, Pages: 1029
screening and cancer. Genetic screening tests, despite some restrictions is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics
Jain PharmaBiotech, Feb 2012, Pages: 225
-specific inhibition
Prognostic and therapeutic significance of gene amplifications
RNAi-based approach for leukemia
Significance of double minutes
Online resources for cancer cytogenetics
The Cancer Genome
Spectra Intelligence, April 2006, Pages: 369
in the treatment of cancer are covered for each of the important classes of cancertherapeutics. Another important focus of this chapter is novel preclinical treatment approaches based on the most recent discoveries
Jain PharmaBiotech, Feb 2012, Pages: 780
of personalized cancer vaccines
Personalized radiation therapy
Molecular diagnostics combined with cancertherapeutics
Aptamers for combined diagnosis and therapeutics of cancer
Role of nanobiotechnology
Decision Resources, Inc., Dec 2008, Pages: 33
on the role of companion diagnostics as threats or opportunities for the NSCLC drug market.
- Outlook: Biomarker discovery and diagnostics development are at the core of novel products in the war on cancer
TriMark Publications, Sep 2011, Pages: 343
detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management
Jain PharmaBiotech, Feb 2012, Pages: 348
approaches to TSE research.
Molecular diagnosticapproach to TSE research
RNAi for knockdown of the bovine prion gene
Chronic wasting disease
Chronic wasting disease in wildlife
Chronic wasting disease
TriMark Publications, July 2011, Pages: 201
A near-term market opportunity for cancer companion diagnostic tests exists in drug selection for cancer therapy. Co-development of molecular diagnostics and targeted therapeutics has already been
TriMark Publications, July 2011, Pages: 335
.2.5.7 BreastCancer
3.2.5.8 Bladder Cancer
3.2.5.9 Ovarian Cancer
3.2.5.10 Molecular Diagnostic Screening Test for Cancer
3.2.5.11 Cervical Cancer
3.2.6 Microbiology Testing Using Molecular Diagnostics
3
Frost & Sullivan, May 2009, Pages: 53
research projects has resulted in noveltherapeutics. As more biomarkers are discovered and their importance known, the need for specific theranostic assays is likely to increase.
However, the high cost associated
Life Science Intelligence, Inc., Jan 2011
-operative surgical probe used in diagnosing, staging, and treating breastcancer, to reduce residual cancer/repeat surgery after breastcancer lumpectomies
- Biological therapeutics for the treatment
Global Industry Analysts, Inc., Aug 2011, Pages: 1305
of application for Biomarkers. Biomarker Research, though currently in nascent stage, has achieved significant progress in the development of diagnostics and therapeutics targeting cancer. The technology
GlobalData, May 2011, Pages: 135
and technology offerings.
While tumor markers have been part of the global cancerdiagnostics market since the 1960s, their popularity as therapeutic targets has only risen in the last few decades, primarily due
Arrowhead Publishers, May 2010, Pages: 261
for a reasonable period of IP exclusivity as well as new pathways for approval of targeted diagnostics, therapeutics and MTT companion diagnostics. Assist in offering novel solutions.
Collaborate with payers
Life Science Intelligence, Inc., Dec 2011, Pages: 605
and sedation and improved patient outcomes in Operating Rooms (ORs) and Intensive Care Units (ICUs)
- The next major step in the treatment of early breastcancer: replacing lumpectomy with a percutaneous
TriMark Publications, Jan 2011, Pages: 1679
Development
The term companion biomarker means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played
Espicom Business Intelligence Ltd, Aug 2008, Pages: 352
arena?
Focus on...opportunities
The cancer biomarker sector will be driven by...
Increases in the number of new cases of a range of cancers due to an aging population, e.g. prostate, breast and ovarian
Datamonitor, April 2010, Pages: 243
of the current small molecule targeted cancer therapies pipeline by developmental phase, drug target and company
-Insight and analysis of market potential including commercial opportunity and discussion of unmet
